Eli Lilly and Company

Hoechst Marion Roussel

Eli Lilly

Shawn Christopher Miller

Matthew Joseph Fisher

Wayne A Spitzer

Jefferson Ray McCowan

Frantz Victor

Mark Joseph Tebbe

Jeffrey Thomas Mullaney

Timothy Paul Burkholder

Joseph P Burkhart

Yanping Xu

Karin Briner

William Harlan Gritton

John M Schaus

Daniel Jon Sall

Gerald Floyd Smith

Leonard Larry Winneroski, Jr

Ho-Shen Lin

Minsheng Zhang

Yao-Chang Xu

Michael Enrico Richett

Richard Waltz Harper

Louis Nickolaus Jungheim

Kumiko Takeuchi

Bruno Giethlen

Robert J Foglesong

Zhaogen Chen

Mary George Johnson

Michael Lyle Denney

Nickolay Y Chirgadze

James Ronald Gillig

Michael Philip Cohen

Michael P Lynch

Matthew Robert Reinhard

Joseph Chiou-Chung Tang

Joseph Matthew Colacino

Brian Eugene Cunningham

Thomas R Sattelberg, Sr

Beverly Ann Heinz

Michael Robert Wiley

Jason Scott Sawyer

Douglas Wade Beight

Alan David Palkowitz

Theodore Goodson, Jr

Valentine Joseph Klimkowski

Jolie Anne Bastian

Cynthia Darshini Jesudason

Sai P Sunkara

Jennifer Marie Tinsley

William Thomas McMillen

Dennis C Thompson

Edward C R Smith

Daniel Timothy Kohlman

Sidney Xi Liang

Alexander Glenn Godfrey

Freddie Craig Stevens

Jeffrey S Sabol

Hong-Yu Li

Roger Ryan Rothhaar

Jonathan Michael Yingling

Todd Vincent Decollo

John Mehnert Schaus

Jefferson Ray Mccowan

The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor. 

N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HTreceptor. The present invention further provides a method of treating disorders associated with 5-HTreceptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

[object Object]

Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S

Pyrrole derivatives as pharmaceutical agents

The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R, R, R, R, R', R, R&#x2032;, and Rare as described in the specification. 

Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists

The present invention provides serotonergic benzofurylpiperazines of Formula I:where:

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and Rare as described in the specification.

Serotonergic benzofurans

The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.

Thrombin inhibitors

##STR1## The present invention is directed to a class of novel carbocyclic derivatives having formulas (I) and (II) and their use as anti-viral and anti-neoplastic agents, wherein X.sub.1 and X.sub.2 are each independently hydrogen, fluorine, or chlorine, R is hydrogen or hydroxymethyl, J is a radical of formulas (a), (b) and (c). Y.sub.1 is a CH group, a CCl group, a CBr group or a CNH.sub.2 group, Y.sub.2 and Y.sub.3 are each independently nitrogen or a CH group, Y.sub.1 is a CH group, a CCl group, a CBr group or a CNH.sub.2 group, Y.sub.2 and Y.sub.3 are each independently nitrogen or a CH group, Y.sub.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or halogen, Y.sub.5 is NH.sub.2 or C.sub.1 -C.sub.4 alkoxy, Q is NH.sub.2, NHOH, NHCH.sub.3, OH, or hydrogen, and V is hydrogen, halogen or NH.sub.2 ; or a pharmaceutically acceptable salt thereof.

Carbo-acyclic nucleoside derivatives as antiviral and antineoplastic

A series of benzimidazole compounds having the following general structure are provided which inhibit the growth of picornaviruses (e.g., rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus) and flaviviruses (e.g., hepatitis C and bovine diarrheal virus). ##STR1## A method for inhibiting picornaviruses and flaviviruses is also provided which includes administering to a host an effective amount of the inventive benzimidazole compounds.

Anti-viral compound

The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus and flaviviruses such as hepatitis C and bovine diarrheal virus.

Anti-viral compounds

Certain vinyl acetylene benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus.

The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.

Growing community of inventors

Noblesville, IN, United States of America

Shawn Christopher Miller